A Case of Cutaneous Leishmaniasis Responding to Systemic Liposomal Amphotericin B Treatment

Taskin E. C., Kutukcu H. B., KONCA H. K., ARGA G., ÖZDEMİR H., AKAY B. N., ...Daha Fazla

JOURNAL OF PEDIATRIC INFECTION, cilt.14, sa.4, ss.247-250, 2020 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5578/ced.69928
  • Dergi Adı: JOURNAL OF PEDIATRIC INFECTION
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.247-250
  • Anahtar Kelimeler: Amphotericin B, cutaneous leishmania, meglumine antimoniate
  • Ankara Üniversitesi Adresli: Evet

Özet

Leishmania is a vector-induced endemic tropical disease caused by protozoans. The most common cutaneous, mucosal and visceral forms are the cutaneous form. The main drugs in treatment are pentavalent antimony compounds, but their side effects create limitation of use. Local antimony compounds are used primarily in the treatment of cutaneous leishmaniasis. In some cases, alternative treatment modalities are required due to insufficient response to local treatment. Systemic amphotericin B treatment is one of the alternative treatments. In a patient who developed cutaneous leishmania at 21 months and who did not respond with local meglumine antimoniate therapy, a total of 21 mg / kg dose of systemic amphotericin B was given intermittently and successful results were obtained.